<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0026-1742</journal-id>
<journal-title><![CDATA[Revista de la Facultad de Medicina (México)]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Fac. Med. (Méx.)]]></abbrev-journal-title>
<issn>0026-1742</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional Autónoma de México, Facultad de Medicina]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0026-17422020000100034</article-id>
<article-id pub-id-type="doi">10.22201/fm.24484865e.2020.63.1.06</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Utilidad de la tomografía por emisión de positrones/ tomografía computada (PET/CT) en pacientes con diagnóstico de meduloblastoma]]></article-title>
<article-title xml:lang="en"><![CDATA[Usefulness of Positron Emission Tomography/Computed Tomography (PET/CT) in Patients Diagnosed with Medulloblastoma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Dávila]]></surname>
<given-names><![CDATA[Rocío Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Bello]]></surname>
<given-names><![CDATA[Sergio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villanueva Rodríguez]]></surname>
<given-names><![CDATA[Raúl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[René López]]></surname>
<given-names><![CDATA[León]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valencia Vázquez]]></surname>
<given-names><![CDATA[Jorge Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivera-Bravo]]></surname>
<given-names><![CDATA[Belén]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional Autónoma de México  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Autónoma de Guerrero Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Acapulco de Juárez Guerrero]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Politécnico Nacional Escuela Nacional de Medicina y Homeopatía ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2020</year>
</pub-date>
<volume>63</volume>
<numero>1</numero>
<fpage>34</fpage>
<lpage>41</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0026-17422020000100034&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0026-17422020000100034&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0026-17422020000100034&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La tomografía por emisión de positrones/tomografía computada (PET/CT) por sus siglas en inglés, es una modalidad de imagen única que proporciona evidencia in vivo de actividades tanto bioquímicas como fisiológicas en diferentes órganos y estructuras del cuerpo. El meduloblastoma es el tumor maligno más frecuente del sistema nervioso central (SNC) en pacientes pediátricos, por este motivo el PET/CT juega un papel importante en el manejo de estos pacientes ya que proporciona información sobre el grado y extensión del tumor, así como a determinar el sitio adecuado para la toma de biopsia, valorar la respuesta al tratamiento y determinar el pronóstico del paciente. Existen diferentes radiofármacos para la evaluación de los tumores de sistema nervioso central, pero se ha estudiado que el 18F-FDG (flúor-2-fluoro-2-desoxi-D-glucosa) y el 68Ga-DOTA-NOC (68Ga-DOTA0-1NaI3-octreotide) nos ayudan a evaluar y dar seguimiento a pacientes con diagnóstico de meduloblastoma. El meduloblastoma tiene una sobreexpresión de transportadores de glucosa, principalmente tipo 1 y sobreexpresión de receptores de somatostatina predominantemente tipo 2, lo cual permite que exista una gran afinidad por estos radiofármacos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: PET/CT (positron emission tomography/computed tomography, for its acronym in English) is a unique imaging method that provides in vivo evidence of both biochemical and physiological activities of the brain, spinal cord and tumors that involve these structures. Medulloblastoma is the most common malignant tumor of the central nervous system (CNS) in pediatric patients, so PET/CT plays an important role as it provides information on the grade and extent of the tumor, as well as to determine the appropriate site for the biopsy, assessing the response to the treatment and the patient&#8217;s prognosis. There are different radiopharmaceuticals for the evaluation of central nervous system tumors, but 18F FDG (Fluor-2-fluoro-2-desoxy-D-glucose) and 68Ga-DOTA-NOC (68Ga-DOTA0-1NaI3-octreotide) have been studied to help us evaluate and follow up patients diagnosed with medulloblastoma. Medulloblastoma has an overexpression of glucose transporters, mainly type 1, and an overexpression of predominantly type 2 somatostatin receptors, which allows a high affinity for these radiopharmaceuticals.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Meduloblastoma]]></kwd>
<kwd lng="es"><![CDATA[tomografía por emisión de positrones]]></kwd>
<kwd lng="es"><![CDATA[PET/CT]]></kwd>
<kwd lng="es"><![CDATA[18F-FDG]]></kwd>
<kwd lng="es"><![CDATA[68Ga-DOTA-NOC]]></kwd>
<kwd lng="es"><![CDATA[tumor cerebral]]></kwd>
<kwd lng="en"><![CDATA[Medulloblastoma]]></kwd>
<kwd lng="en"><![CDATA[positron emission tomography]]></kwd>
<kwd lng="en"><![CDATA[PET/C]]></kwd>
<kwd lng="en"><![CDATA[18F-FDG]]></kwd>
<kwd lng="en"><![CDATA[68Ga-DOTA-NOC]]></kwd>
<kwd lng="en"><![CDATA[brain tumor]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivera-luna]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Niembro-zúñiga]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Zarco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marhx-bracho]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meduloblastoma en pediatría]]></article-title>
<source><![CDATA[Pronóstico y tratamiento en la actualidad]]></source>
<year>2007</year>
<volume>143</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>415-20</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alegría-Loyola]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Andrés Galnares-Olalde]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Tumores del sistema nervioso central* Tumors of the central nervous system]]></source>
<year>2017</year>
<volume>55</volume>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinning]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clasificación De los Tumores Cerebrales]]></article-title>
<source><![CDATA[Rev Médica Clínica Las Condes]]></source>
<year>2017</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>339-42</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez León]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meduloblastoma pediátrico, revisión y puesta al día]]></article-title>
<source><![CDATA[Radiología]]></source>
<year>2010</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>134-45</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vezina]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of and prognosis with medulloblastoma therapy at a crossroads]]></article-title>
<source><![CDATA[Arch Neurol]]></source>
<year>2008</year>
<volume>65</volume>
<page-range>1419-24</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zukotynski]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fahey]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kocak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kun]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Boyett]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fouladi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2014</year>
<volume>55</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1473-80</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gururangan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Herendon JE]]></surname>
<given-names><![CDATA[II]]></given-names>
</name>
<name>
<surname><![CDATA[Fuchs]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Coleman]]></surname>
<given-names><![CDATA[RE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[[18F] fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma]]></article-title>
<source><![CDATA[Neurosurgery]]></source>
<year>2004</year>
<volume>55</volume>
<page-range>1280-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yüksel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lutterbey]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Biersack]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Elke]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Hasan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[111In-pentetreotide scintigraphy in medulloblastoma a comparison with magnetic resonance imaging]]></article-title>
<source><![CDATA[Acta Oncol]]></source>
<year>2007</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>111-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaidyanathan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Affleck]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[XG]]></given-names>
</name>
<name>
<surname><![CDATA[Keir]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Zalutsky]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[(177Lu) .- DOTAO-Tyr3-octreotate: a potential targeted radiotherapeutic for the treatment of meduloblastoma]]></article-title>
<source><![CDATA[Curr Radiopharm]]></source>
<year>2010</year>
<volume>3</volume>
<page-range>29-36</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Carbajal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroimagen funcional Combinación de anatomía y fisiología: I. Introducción]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2002</year>
<volume>138</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>247-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[McConathy]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overview of PET tracers for brain tumor imaging]]></article-title>
<source><![CDATA[PET Clin]]></source>
<year>2013</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>129-46</page-range><publisher-name><![CDATA[Elsevier Inc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thust]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pseudoprogression of brain tumors]]></article-title>
<collab>van den Bent MJ.Smits M</collab>
<source><![CDATA[J Magn Reson Imaging]]></source>
<year>2018</year>
<volume>48</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>571-89</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Van den Bent]]></surname>
<given-names><![CDATA[MJ.]]></given-names>
</name>
<name>
<surname><![CDATA[Macdonald]]></surname>
<given-names><![CDATA[DR.]]></given-names>
</name>
<name>
<surname><![CDATA[Vogelbaum]]></surname>
<given-names><![CDATA[MA.]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[EQ.]]></given-names>
</name>
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[PY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Response Assessment in Neuro-Oncology Clinical Trials]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2017</year>
<volume>35</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2439-49</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dunet]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Prior]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FET PET in neuro-oncology and in evaluation of treatment response]]></article-title>
<source><![CDATA[PET Clin]]></source>
<year>2013</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>147-62</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suárez Fernández]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado Suárez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez Grande]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Serna Macías]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Kostvinseva]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ordovás Oromendía]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La Tomografía por Emisión de Positrones (PET) en la práctica clínica oncológica]]></article-title>
<source><![CDATA[Oncol]]></source>
<year>2004</year>
<volume>27</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>479-89</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Estela Herrera-González]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-García]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mejía-Jiménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Estela]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El efecto Warburg: la mano derecha en el desarrollo del cáncer]]></article-title>
<source><![CDATA[Rev Esp Méd Quir]]></source>
<year>2015</year>
<volume>20</volume>
<page-range>171-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Weller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Suchorska]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Galldiks]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Soffietti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Response assessment in neuro-oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas]]></article-title>
<source><![CDATA[Neuro-Oncology]]></source>
<year>2016</year>
<volume>18</volume>
<page-range>1199-208</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reichlin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Somatostatin]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1983</year>
<volume>309</volume>
<page-range>1495-501</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Epelbaum]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dournaud]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fodor]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Crit Rev]]></article-title>
<collab>Viollet C: The neurobiology of somatostatin</collab>
<source><![CDATA[Neurobiol]]></source>
<year>1994</year>
<volume>8</volume>
<page-range>25-44</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dutour]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Panetta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of somatostatin receptor subtypes in human brain tumors]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>1998</year>
<volume>76</volume>
<page-range>620-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frühwald]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Rickert]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[O'Dorisio]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2004</year>
<volume>10</volume>
<page-range>2997-3006</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reubi]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Koper]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Lamberts]]></surname>
<given-names><![CDATA[SWJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>1987</year>
<volume>47</volume>
<page-range>5758-64</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cervera]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Videau]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Viollet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Petrucci]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lacombe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Winsky-Sommerer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of somatostatin receptor expression in human gliomas and medulloblastomas]]></article-title>
<source><![CDATA[J Neuroendocrinol]]></source>
<year>2002</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>458-71</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Frühwald]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Scheubeck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rendl]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Warmuth-Metz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sörensen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Posible papel de la gammagrafía con receptores de somatostatina en el diagnóstico y seguimiento de niños con meduloblastoma]]></article-title>
<source><![CDATA[J Neurooncol]]></source>
<year>1998</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-40</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wild]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schmitt]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Ginj]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2003</year>
<volume>30</volume>
<page-range>1338-47</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Virgolini]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ambrosini]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bomanji]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides 68Ga-DOTATOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2010</year>
<volume>37</volume>
<page-range>2004-10</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weinstock]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The somatostatin immunoregulatory circuit present at sites of chronic inflammation]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2000</year>
<volume>143</volume>
<page-range>S15-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
